Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ATXI

Avenue Therapeutics Inc

Dec 10 • 04:00PM ET

1.90

Dollar change +0.07
Percentage change 3.83	%

Healthcare • Biotechnology • USA • NASD

Peers: PCRX HRTX EOLS XENE MRNS PTGX VKTX RDHL VERU TGTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-14.20	Insider Own	14.15%	Shs Outstand	2.05M	Perf Week	1.60%
Market Cap	3.90M	Forward P/E	-	EPS next Y	-1.96	Insider Trans	0.14%	Shs Float	1.76M	Perf Month	-13.24%
Income	-13.96M	PEG	-	EPS next Q	-0.57	Inst Own	9.62%	Short Float	2.50%	Perf Quarter	-34.48%
Sales	0.00M	P/S	-	EPS this Y	91.51%	Inst Trans	-	Short Ratio	0.99	Perf Half Y	-44.61%
Book/sh	1.63	P/B	1.17	EPS next Y	68.59%	ROA	-893.00%	Short Interest	0.04M	Perf Year	-83.50%
Cash/sh	1.27	P/C	1.50	EPS next 5Y	-	ROE	-1037.72%	52W Range	1.60 - 26.47	Perf YTD	-84.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.07%	ROI	-534.94%	52W High	-92.82%	Beta	-0.27
Dividend TTM	-	Quick Ratio	2.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.75%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	2.70	EPS Y/Y TTM	86.45%	Oper. Margin	-	RSI (14)	43.16	Volatility	5.33% 7.16%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-139.54%	Payout	-	Rel Volume	0.15	Prev Close	1.83
Sales Surprise	-	EPS Surprise	-104.26%	Sales Q/Q	-	Earnings	Nov 14 AMC	Avg Volume	44.47K	Price	1.90
SMA20	-2.81%	SMA50	-8.86%	SMA200	-59.15%	Trades		Volume	6,591	Change	3.83%

Nov-14-24 04:05PM	Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Oct-09-24 08:30AM	Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit (GlobeNewswire)
Sep-03-24 08:30AM	Avenue Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +9.84%
Aug-13-24 04:05PM	Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-09-24 08:53PM	ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024 (InvestorPlace) +5.77%
04:05PM	Loading…
04:05PM	Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-20-24 08:30AM	Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire) -5.79%
May-16-24 08:30AM	Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
May-15-24 09:55PM	ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:30AM	Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-29-24 08:00AM	Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds (GlobeNewswire) -27.18%
Apr-24-24 07:30AM	Avenue Therapeutics Announces Reverse Stock Split (GlobeNewswire) -29.63%
Mar-25-24 08:30AM	Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 (GlobeNewswire)
Mar-19-24 06:53AM	ATXI Stock Earnings: Avenue Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Mar-18-24 04:05PM	Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
08:15AM	Loading…
Mar-15-24 08:15AM	Avenue Therapeutics Receives Positive Listing Determination from Nasdaq (GlobeNewswire)
Mar-11-24 08:00AM	Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting (GlobeNewswire) -15.62%
Feb-22-24 08:30AM	Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy (GlobeNewswire)
Jan-16-24 08:40AM	Sidoti Events, LLC's Virtual January Micro-Cap Conference (ACCESSWIRE) -11.03%
Jan-11-24 08:00AM	Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference (GlobeNewswire)
Jan-05-24 09:15AM	Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds (GlobeNewswire) -44.64%
Jan-04-24 08:30AM	Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol (GlobeNewswire) +95.71%
Jan-02-24 08:30AM	Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Dec-01-23 08:30AM	Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting (GlobeNewswire) -9.43%
Nov-29-23 08:05AM	Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today? (InvestorPlace) -6.99%
Nov-13-23 04:05PM	Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire) -12.20%
Nov-02-23 03:00PM	Avenue Therapeutics Announces Closing of $5.0 Million Public Offering (GlobeNewswire)
Oct-31-23 09:15AM	Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -33.07%
Sep-05-23 08:30AM	Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -6.40%
Aug-14-23 04:01PM	Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
04:15PM	Loading…
Aug-10-23 04:15PM	Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Aug-01-23 08:30AM	Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study (GlobeNewswire)
Jul-27-23 08:30AM	Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) (GlobeNewswire)
Jul-25-23 08:30AM	Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol (GlobeNewswire)
May-15-23 04:01PM	Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-12-23 08:30AM	Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-27-23 08:30AM	Avenue Therapeutics to Present at Aegis Capital Virtual Conference (GlobeNewswire)
Apr-17-23 04:01PM	Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol (GlobeNewswire) +5.50% -6.09%
Mar-30-23 04:10PM	Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +5.91%
04:01PM	Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-08-23 04:01PM	Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates (GlobeNewswire) +17.31%
Mar-02-23 08:00AM	Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy (GlobeNewswire)
Jan-31-23 01:30PM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI) (ACCESSWIRE)
01:09PM	Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement (GlobeNewswire)
Jan-27-23 11:58AM	Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules (GlobeNewswire) -10.97%
Nov-10-22 04:10PM	Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights (GlobeNewswire) +12.23% -10.43%
Nov-08-22 12:26PM	Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio (Benzinga)
08:30AM	Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A 2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders (GlobeNewswire)
Oct-12-22 10:25AM	Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI) (ACCESSWIRE) -10.56%
Oct-11-22 02:15PM	Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering (GlobeNewswire) +10.08%
Oct-06-22 11:00PM	Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering (GlobeNewswire) -25.74% -57.71%
Oct-03-22 08:00AM	Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer (GlobeNewswire) +14.19%
Sep-23-22 08:51AM	Avenue Therapeutics Announces Reverse Stock Split, Regulatory Update For Lead Its Pain Candidate (Benzinga) -31.82%
Sep-22-22 04:25PM	Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA (GlobeNewswire) +105.90%
Mar-31-22 07:30AM	Abeona Therapeutics Announces Strategy Update and 2021 Financial Results (GlobeNewswire) -6.29%
Feb-16-22 08:20AM	FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol (Benzinga) -48.69%
Feb-15-22 10:00PM	Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol (GlobeNewswire)
07:05AM	Avenue Therapeutics Stock Trading Halted Today (GlobeNewswire)
Dec-15-21 02:15PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) (ACCESSWIRE) -10.77%
12:00PM	Avenue Therapeutics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Dec-12-21 08:00PM	Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Nov-29-21 08:00AM	Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022 (GlobeNewswire) +53.15%
Nov-17-21 09:30AM	Avenue Therapeutics Announces Exercise and Closing of Underwriters Over-Allotment Option (GlobeNewswire)
Nov-12-21 10:40AM	Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI) (ACCESSWIRE)
09:20AM	Avenue Therapeutics Announces Closing of Public Offering of Common Stock (GlobeNewswire)
Nov-09-21 09:30PM	Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -8.14% -18.35%
Oct-25-21 07:00AM	Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs (GlobeNewswire) +25.40%
Aug-26-21 11:04AM	Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study (Zacks)
Jun-21-21 08:04AM	Mondays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks)
Jun-14-21 08:42AM	Mondays Pre-Market: Heres What You Need to Know Before the Market Opens (TipRanks) -28.27%
07:44AM	CORRECTED-U.S. FDA declines to approve Avenue's painkiller again, shares drop (Reuters)
07:00AM	Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol (GlobeNewswire)
Apr-26-21 08:09AM	BioRad (BIO) to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-23-21 11:36PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (GlobeNewswire)
09:43AM	What's in Store for Perrigo (PRGO) This Earnings Season? (Zacks)
08:41AM	ResMed (RMD) to Report Q3 Earnings: What's in the Offing? (Zacks)
Apr-22-21 10:59AM	Integra (IART) to Report Q1 Earnings: What's in the Offing? (Zacks)
Apr-21-21 10:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (Newsfile) +16.37%
09:38AM	VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid (Zacks)
Apr-19-21 10:09PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire) -12.53%
06:26AM	Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy? (Zacks)
Apr-16-21 11:25PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Apr-14-21 10:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (GlobeNewswire) -11.99%
Apr-13-21 11:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire) -23.77%
03:09PM	Why Fortress Biotech Stock Is Sinking Today (Motley Fool)
02:30PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Avenue Therapeutics, Inc. (ATXI) Investigation (ACCESSWIRE)
09:33AM	JAZZ's Xywav sNDA for Hypersomnia Gets FDA Priority Review (Zacks)
06:30AM	Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol (GlobeNewswire)
Apr-12-21 01:36AM	Is Avenue Therapeutics (NASDAQ:ATXI) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-11-21 11:32PM	How Much Of Avenue Therapeutics, Inc. (NASDAQ:ATXI) Do Institutions Own? (Simply Wall St.)
Jan-06-21 09:23AM	Is Avenue Therapeutics (ATXI) Stock a Buy For 2021? (Insider Monkey)
Dec-18-20 08:00AM	Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis (GlobeNewswire) +15.41%
08:00AM	Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network (GlobeNewswire)
Dec-17-20 04:27PM	Why Fortress Biotech Stock Jumped Today (Motley Fool) +47.70%
07:00AM	Avenue Therapeutics Provides Regulatory Update for IV Tramadol (GlobeNewswire)
Nov-13-20 05:28AM	Read This Before Selling Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares (Simply Wall St.)
Oct-28-20 07:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE)
Oct-23-20 10:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (ACCESSWIRE) -6.36%
Oct-14-20 08:58PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI (PR Newswire)
10:10AM	Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates (Zacks)

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herskowitz Neil	Director	Dec 02 '24	Sale	2.00	23	46	97	Dec 03 04:30 PM
KRANZLER JAY D	Director	Nov 05 '24	Sale	2.24	61	137	559	Nov 07 07:12 PM
KRANZLER JAY D	Director	Sep 30 '24	Buy	2.50	497	1,242	620	Oct 01 04:15 PM
KRANZLER JAY D	Director	Sep 27 '24	Buy	2.40	3	7	123	Oct 01 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATXI

Avenue Therapeutics Inc

Upgrade your FINVIZ experience